Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$69.35
À la fermeture: Oct 24 EDT
$69.43
0.080.11%
Pré-commercialisation: 8:16 AM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Guardant Health Inc a un objectif de cours consensus de $61.39, basé sur les évaluations des 32 analystes. Le plus élevé est de $90 attribué par Piper Sandler le octobre 22, 2025, et le plus bas est de $32 attribué par Jefferies le juin 3, 2024. Les 3 dernières évaluations d'analystes ont été publiées par Piper Sandler, Evercore ISI Group et Barclays le octobre 22, 2025, octobre 7, 2025 et octobre 2, 2025. Avec un objectif de cours moyen de $76 entre Piper Sandler, Evercore ISI Group et Barclays, il y a une variation implicite de 9.47% upside pour Guardant Health Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Piper Sandler
Evercore ISI Group
Barclays
Canaccord Genuity
TD Cowen
1calculé à partir des notes des analystes
Notes d'analystes pour Guardant Health
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/22/2025 | 29.63% | Piper Sandler | $60 → $90 | Maintains | Overweight | |||
10/07/2025 | -2.06% | Evercore ISI Group | $60 → $68 | Maintains | Outperform | |||
10/02/2025 | 0.82% | Barclays | $60 → $70 | Maintains | Overweight | |||
09/26/2025 | 8.03% | Canaccord Genuity | $65 → $75 | Maintains | Buy | |||
09/25/2025 | 3.71% | TD Cowen | $63 → $72 | Maintains | Buy | |||
09/25/2025 | 0.82% | Stifel | $60 → $70 | Maintains | Buy | |||
09/25/2025 | 8.03% | Leerink Partners | $70 → $75 | Maintains | Outperform | |||
09/25/2025 | 0.82% | Mizuho | $65 → $70 | Maintains | Outperform | |||
09/25/2025 | 8.03% | Wolfe Research | → $75 | Upgrade | Peer Perform → Outperform | |||
09/25/2025 | 15.23% | UBS | $70 → $80 | Maintains | Buy | |||
09/25/2025 | -3.5% | Guggenheim | $56 → $67 | Maintains | Buy | |||
09/25/2025 | 0.82% | JP Morgan | $60 → $70 | Maintains | Overweight | |||
09/25/2025 | 15.23% | BTIG | $70 → $80 | Maintains | Buy | |||
09/22/2025 | 3.71% | Wells Fargo | → $72 | Initiates | → Overweight | |||
09/22/2025 | 0.82% | BTIG | $70 → $70 | Reiterates | Buy → Buy | |||
09/04/2025 | 0.82% | BTIG | $65 → $70 | Maintains | Buy | |||
07/31/2025 | -13.58% | Scotiabank | $57 → $60 | Maintains | Sector Outperform | |||
07/31/2025 | -12.14% | Raymond James | $59 → $61 | Maintains | Outperform | |||
06/13/2025 | -6.38% | Mizuho | $60 → $65 | Maintains | Outperform | |||
05/06/2025 | -13.58% | Piper Sandler | $50 → $60 | Maintains | Overweight | |||
05/05/2025 | -17.9% | Scotiabank | $52 → $57 | Maintains | Sector Outperform | |||
05/01/2025 | -6.38% | Canaccord Genuity | $60 → $65 | Maintains | Buy | |||
05/01/2025 | -13.58% | Stifel | $53 → $60 | Maintains | Buy | |||
05/01/2025 | -13.58% | Barclays | $55 → $60 | Maintains | Overweight | |||
05/01/2025 | -13.58% | TD Securities | $56 → $60 | Maintains | Buy | |||
05/01/2025 | 0.82% | UBS | $65 → $70 | Maintains | Buy | |||
04/10/2025 | -20.78% | Barclays | $60 → $55 | Maintains | Overweight | |||
04/10/2025 | -20.78% | Mizuho | → $55 | Initiates | → Outperform | |||
03/26/2025 | -20.78% | Stephens & Co. | $55 → $55 | Reiterates | Overweight → Overweight | |||
03/06/2025 | -25.1% | Morgan Stanley | $42 → $52 | Maintains | Overweight | |||
02/26/2025 | -27.98% | Piper Sandler | $34 → $50 | Maintains | Overweight | |||
02/24/2025 | -19.34% | Guggenheim | $56 → $56 | Reiterates | Buy → Buy | |||
02/24/2025 | -25.1% | Scotiabank | $47 → $52 | Maintains | Sector Outperform | |||
02/24/2025 | -13.58% | Canaccord Genuity | $42 → $60 | Maintains | Buy | |||
02/21/2025 | -19.34% | Goldman Sachs | $49 → $56 | Maintains | Buy | |||
02/21/2025 | -15.02% | Raymond James | $39 → $59 | Reiterates | Outperform → Outperform | |||
02/21/2025 | -20.78% | JP Morgan | $50 → $55 | Maintains | Overweight | |||
02/21/2025 | -23.66% | Stifel | $45 → $53 | Maintains | Buy | |||
01/28/2025 | -29.42% | Goldman Sachs | $36 → $49 | Maintains | Buy | |||
01/23/2025 | -13.58% | Barclays | → $60 | Initiates | → Overweight | |||
01/22/2025 | — | Guggenheim | — | Reiterates | Buy → Buy | |||
11/07/2024 | -27.98% | JP Morgan | $48 → $50 | Maintains | Overweight | |||
11/07/2024 | -48.15% | Goldman Sachs | $32 → $36 | Maintains | Buy | |||
10/30/2024 | -49.59% | Bernstein | $40 → $35 | Maintains | Outperform | |||
10/17/2024 | -27.98% | Leerink Partners | — | $60 → $50 | Maintains | Outperform | ||
08/21/2024 | -42.39% | UBS | $32 → $40 | Maintains | Buy | |||
08/13/2024 | -51.03% | Piper Sandler | $30 → $34 | Maintains | Overweight | |||
08/08/2024 | -35.18% | Citigroup | $40 → $45 | Maintains | Buy | |||
08/08/2024 | -39.51% | TD Cowen | $41 → $42 | Maintains | Buy | |||
08/08/2024 | -46.71% | Craig-Hallum | $28 → $37 | Maintains | Buy | |||
08/08/2024 | -30.86% | JP Morgan | $45 → $48 | Maintains | Overweight | |||
07/30/2024 | -27.98% | BTIG | $45 → $50 | Maintains | Buy | |||
07/29/2024 | -39.51% | Canaccord Genuity | $38 → $42 | Maintains | Buy | |||
07/18/2024 | -42.39% | B of A Securities | $28 → $40 | Maintains | Buy | |||
07/17/2024 | -53.91% | Goldman Sachs | $28 → $32 | Maintains | Buy | |||
06/28/2024 | -48.15% | Guggenheim | → $36 | Upgrade | Neutral → Buy | |||
06/04/2024 | -45.27% | Canaccord Genuity | $30 → $38 | Maintains | Buy | |||
06/03/2024 | -53.91% | Jefferies | → $32 | Initiates | → Buy | |||
05/24/2024 | -36.62% | Stephens & Co. | $44 → $44 | Reiterates | Overweight → Overweight | |||
04/29/2024 | -56.79% | Canaccord Genuity | $45 → $30 | Maintains | Buy | |||
04/24/2024 | -59.67% | Craig-Hallum | → $28 | Assumes | → Buy | |||
04/15/2024 | -59.67% | Goldman Sachs | $32 → $28 | Maintains | Buy | |||
04/05/2024 | — | Guggenheim | — | Reiterates | → Neutral | |||
02/26/2024 | -56.79% | Piper Sandler | $40 → $30 | Maintains | Overweight | |||
02/23/2024 | -35.18% | JP Morgan | $60 → $45 | Maintains | Overweight | |||
02/23/2024 | -35.18% | Canaccord Genuity | $50 → $45 | Maintains | Buy | |||
01/30/2024 | -46.71% | Goldman Sachs | $43 → $37 | Maintains | Buy | |||
01/29/2024 | -46.71% | Goldman Sachs | $43 → $37 | Maintains | Buy | |||
12/14/2023 | — | Guggenheim | — | Initiates | → Neutral | |||
12/13/2023 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/13/2023 | -61.11% | Raymond James | → $27 | Upgrade | Market Perform → Outperform | |||
11/08/2023 | -27.98% | Morgan Stanley | $55 → $50 | Maintains | Overweight | |||
10/23/2023 | -35.18% | Goldman Sachs | $52 → $45 | Maintains | Buy | |||
10/20/2023 | -35.18% | Goldman Sachs | $52 → $45 | Maintains | Buy | |||
10/02/2023 | -27.98% | Citigroup | $50 → $50 | Reiterates | Buy → Buy | |||
09/28/2023 | -51.03% | Bernstein | → $34 | Initiates | → Outperform | |||
09/27/2023 | -42.39% | Piper Sandler | → $40 | Upgrade | Neutral → Overweight | |||
08/08/2023 | -42.39% | Piper Sandler | $30 → $40 | Maintains | Neutral | |||
08/07/2023 | -20.78% | Morgan Stanley | $60 → $55 | Maintains | Overweight | |||
08/04/2023 | -27.98% | Citigroup | $40 → $50 | Maintains | Buy | |||
05/26/2023 | -42.39% | Citigroup | → $40 | Upgrade | Neutral → Buy | |||
05/11/2023 | -13.58% | Morgan Stanley | $66 → $60 | Maintains | Overweight | |||
05/10/2023 | -20.78% | Credit Suisse | $60 → $55 | Maintains | Outperform | |||
05/01/2023 | — | OTR Global | — | — | Downgrade | Mixed → Negative | ||
03/09/2023 | -52.47% | Citigroup | $60 → $33 | Downgrade | Buy → Neutral | |||
03/03/2023 | -49.59% | Piper Sandler | $50 → $35 | Maintains | Neutral | |||
02/27/2023 | -4.94% | Morgan Stanley | $73 → $66 | Maintains | Overweight | |||
02/24/2023 | -27.98% | BTIG | $60 → $50 | Maintains | Buy | |||
02/24/2023 | -13.58% | Canaccord Genuity | $65 → $60 | Maintains | Buy | |||
02/24/2023 | -23.66% | Cowen & Co. | $70 → $53 | Maintains | Outperform | |||
02/24/2023 | -6.38% | JP Morgan | $75 → $65 | Maintains | Overweight | |||
02/24/2023 | -13.58% | Credit Suisse | $70 → $60 | Maintains | Outperform | |||
02/21/2023 | 5.15% | Morgan Stanley | $80 → $73 | Maintains | Overweight | |||
02/16/2023 | -9.26% | Stephens & Co. | → $63 | Reiterates | → Overweight | |||
02/06/2023 | -35.18% | Goldman Sachs | $70 → $45 | Maintains | Buy | |||
01/05/2023 | -48.15% | Scotiabank | → $36 | Initiates | → Sector Outperform | |||
11/18/2022 | 22.43% | JP Morgan | $100 → $85 | Maintains | Overweight | |||
11/07/2022 | 29.63% | Stephens & Co. | $99 → $90 | Maintains | Overweight | |||
11/04/2022 | 0.82% | Goldman Sachs | $80 → $70 | Maintains | Buy | |||
11/04/2022 | 0.82% | Credit Suisse | $80 → $70 | Maintains | Outperform |
FAQ
Quel est le cours indicatif de l'action Guardant Health (GH) ?
Le dernier objectif de prix pour Guardant Health (NASDAQ:GH) a été rapporté par Piper Sandler le octobre 22, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $90.00 s'attendant à ce que GH se rise dans les 12 prochains mois (un possible changement de 29.63% upside). 44 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Guardant Health (GH) ?
La dernière note d'analyste pour Guardant Health (NASDAQ:GH) a été fournie par Piper Sandler, et Guardant Health maintenu leur note overweight.
Quand a eu lieu la dernière mise à niveau pour Guardant Health (GH) ?
La dernière amélioration pour Guardant Health Inc a eu lieu le septembre 25, 2025 lorsque Wolfe Research a augmenté leur objectif de prix à $75. Wolfe Research avait précédemment a peer perform pour Guardant Health Inc.
Quand a eu lieu la dernière dégradation pour Guardant Health (GH) ?
La dernière réduction pour Guardant Health Inc a eu lieu le mai 1, 2023 lorsque OTR Global a changé leur objectif de prix de N/A à N/A pour Guardant Health Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Guardant Health (GH) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Guardant Health, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Guardant Health a été déposée le octobre 22, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 22, 2026.
La note d'analyste pour Guardant Health (GH) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Guardant Health (GH) était un maintenu avec un objectif de prix de $60.00 à $90.00. Le prix actuel de Guardant Health (GH) est de $69.43, ce qui est within la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.